Alnylam Pharmaceuticals (WBO:ALNY) Cyclically Adjusted PB Ratio: (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:ALNY Alnylam Pharmaceuticals Inc WBO:ALNY
18 GF Score
Price €214.10
GF Value €461.86
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alnylam Pharmaceuticals  (WBO:ALNY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.79 18.66 15.53 21.33 42.42

Alnylam Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.05 46.74 42.42 35.69 32.78

WBO:ALNY vs : Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


WBO:ALNY
18GF Score
Alnylam Pharmaceuticals Inc WBO:ALNY
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Alnylam Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=8.789/333.9520*333.9520
=8.789

Current CPI (Jun. 2026) = 333.9520.

Alnylam Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 10.544 241.428 14.585
201612 10.151 241.432 14.041
201703 9.026 243.801 12.364
201706 10.899 244.955 14.859
201709 9.618 246.819 13.013
201712 14.976 246.524 20.287
201803 14.165 249.554 18.956
201806 13.796 251.989 18.283
201809 12.546 252.439 16.597
201812 11.311 251.233 15.035
201903 12.867 254.202 16.904
201906 13.996 256.143 18.248
201909 13.108 256.759 17.049
201912 11.542 256.974 14.999
202003 10.794 258.115 13.965
202006 10.748 257.797 13.923
202009 8.882 260.280 11.396
202012 7.175 260.474 9.199
202103 6.631 264.877 8.360
202106 5.972 271.696 7.340
202109 5.378 274.310 6.547
202112 4.331 278.802 5.188
202203 3.017 287.504 3.504
202206 1.376 296.311 1.551
202209 -0.555 296.808 -0.624
202212 -1.205 296.797 -1.356
202303 -1.949 301.836 -2.156
202306 -3.016 305.109 -3.301
202309 -1.239 307.789 -1.344
202312 -1.608 306.746 -1.751
202403 -1.595 312.332 -1.705
202406 -0.022 314.175 -0.023
202409 0.226 315.301 0.239
202412 0.496 315.605 0.525
202503 0.819 319.799 0.855
202506 1.659 322.561 1.718
202509 1.512 324.800 1.555
202512 5.091 324.054 5.247
202603 6.971 330.213 7.050
202606 8.789 333.952 8.789

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Alnylam Pharmaceuticals (WBO:ALNY) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of €214.10 is trading 53.6% below its estimated GF Value™ of €461.86. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for WBO:ALNY:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €461.86 vs. price of €214.10 (53.6% below fair value)
  • GF Score™: 18/100 with 1 warning sign

No single metric tells the full story. See the WBO:ALNY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alnylam Pharmaceuticals Business Description

Comparable Companies
Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
18GF Score

Get the complete analysis for WBO:ALNY

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€214.10
Price
€461.86
GF Value